Table 1.
Patients’ characteristics.
| Variables | Dasatinib, N (%) | Nilotinib, N (%) | Imatinib, N (%) | P value |
|---|---|---|---|---|
| Patient number | 43 (11.7) | 102 (27.6) | 225 (60.8) | |
| First-line therapy | 2 (4.7) | 69 (67.6) | 225 (100) | <0.001 |
| Second-line therapy* | 29 (67.4) | 29 (28.4) | 0 | |
| Third-line therapy** | 12 (27.9) | 4 (3.9) | 0 | |
| Male | 29 (67.4) | 66 (64.7) | 144 (64.0) | 0.910 |
| Age, median (range), year | 32 (18–68) | 35 (18–74) | 38 (18–80) | 0.346 |
| 18–<30 | 14 (32.6) | 30 (29.4) | 70 (31.1) | |
| 30–<40 | 17 (39.5) | 30 (29.4) | 57 (25.3) | |
| 40–49 | 7 (16.3) | 24 (23.5) | 52 (23.1) | |
| 50–59 | 2 (4.7) | 14 (13.7) | 30 (13.3) | |
| ≥60 | 3 (7.0) | 4 (3.9) | 16 (7.1) | |
| Interval from diagnosis to starting TKI-therapy (months) | 0.001 | |||
| <6 | 30 (69.8) | 89 (87.3) | 204 (90.7) | |
| ≥6 | 13 (30.2) | 13 (12.7) | 21 (9.3) | |
| Interval from diagnosis to current TKI-therapy (months) | <0.001 | |||
| <6 | 11 (25.6) | 62 (60.8) | 204 (90.7) | |
| ≥6 | 32 (74.4) | 40 (39.2) | 21 (9.3) | |
| Dosage reduction | 3 (7.0) | 25 (24.5) | 21 (9.3) | <0.001 |
| Therapy duration, median (range), months | 24 (3–114) | 21 (3–90) | 48 (3–188) | <0.001 |
Abbreviation: TKI, tyrosine kinase inhibitor.
*As the second-line TKI therapy, imatinib and then dasatinib, n = 28; nilotinib and then dastinib, n = 1; imatinib and then nilotinib, n = 29.
**As the third-line TKI therapy, imatinib, nilotinib and then dasatinib, n = 12; imatinib, dasatinib and then nilotinib, n = 4.